Compare AMTB & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMTB | PHVS |
|---|---|---|
| Founded | 1979 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 857.5M | 1.7B |
| IPO Year | N/A | 2021 |
| Metric | AMTB | PHVS |
|---|---|---|
| Price | $20.93 | $25.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | $22.25 | ★ $39.44 |
| AVG Volume (30 Days) | 239.0K | ★ 245.7K |
| Earning Date | 01-22-2026 | 11-12-2025 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.59 | N/A |
| Revenue | ★ $388,504,000.00 | N/A |
| Revenue This Year | $61.42 | N/A |
| Revenue Next Year | $2.10 | N/A |
| P/E Ratio | $12.87 | ★ N/A |
| Revenue Growth | ★ 51.98 | N/A |
| 52 Week Low | $15.62 | $11.51 |
| 52 Week High | $24.40 | $29.80 |
| Indicator | AMTB | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 49.30 |
| Support Level | N/A | $25.28 |
| Resistance Level | N/A | $26.68 |
| Average True Range (ATR) | 0.00 | 1.50 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 0.00 | 35.14 |
Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.